TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3523551

Group type: EXPERIMENTAL
Intervention: Helium-neon (He-Ne) laser treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 30
Study: 30286507

Group type: EXPERIMENTAL
Intervention: Short term cognitive psychotherapy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Initial attachment characteristics
Number of subjects: 88
Study: 27015689

Group type: EXPERIMENTAL
Intervention: Motor and cognitive rehabilitation (20-week programme consisting of active self-correction, task-oriented exercises, and cognitive-behavioural therapy)
Number of subjects: 130

Group type: COMPARATOR
Intervention: General physiotherapy (active and passive mobilizations, stretching, and strengthening exercises of the spinal muscles)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Motor and cognitive rehabilitation
Number of subjects: 130
Study: 24336884

Group type: EXPERIMENTAL
Intervention: Dietary nitrate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acetazolamide (AZ)
Number of subjects: 20
Study: 22419263

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TA) group (n = 25, 500 mg/5 ml tranexamic acid)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n = 25, 5 ml 0.9% saline)
Number of subjects: 50
Study: 20013115

Group type: EXPERIMENTAL
Intervention: 3 mg regular release (RR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 mg sustained release (SR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 mg surge-sustained release (SSR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18684855

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg twice a day for 12 weeks
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 17117564

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for 3-4 weeks, 5 times each week, plus routine therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine therapy alone
Number of subjects: 40
Study: 14685287

Group type: EXPERIMENTAL
Intervention: Bolus group (10 units of oxytocin administered over 30 seconds)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Drip group (10 units of oxytocin administered over 5 minutes)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no oxytocin administration)
Number of subjects: 90
Study: 10588557

Group type: EXPERIMENTAL
Intervention: Lidocaine alone (group I)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine + epinephrine (group II)
Number of subjects: 20
Study: 8916620

Group type: EXPERIMENTAL
Intervention: Generalized estimating equations (GEE) method for controlling within-cluster correlation in regression models.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GEE-independent method
Number of subjects: 0
Study: 1676715

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 25
Study: 6408300

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no nitroglycerin)
Number of subjects: 60
Study: 31194704

Group type: EXPERIMENTAL
Intervention: Financial Incentives (FI)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 76
Study: 28284785

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab
Number of subjects: 468
Study: 25552412

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 10 mL 10% calcium gluconate in 100 mL 0.9% saline solution
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo group received 100 mL 0.9% saline solution
Number of subjects: 200
Study: 23330988

Group type: EXPERIMENTAL
Intervention: Implant-supported fixed prostheses (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Overdentures (Group B)
Number of subjects: 40
Study: 20869050

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 631

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 631
Study: 19103360

Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NB UVB)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Medium-dose ultraviolet A1 (MD UVA1)
Number of subjects: 13
Study: 17276866

Group type: EXPERIMENTAL
Intervention: Conventional resin-based composite adhesive
Number of subjects: 30

Group type: COMPARATOR
Intervention: ACP-containing orthodontic adhesive
Number of subjects: 30
Study: 15851868

Group type: EXPERIMENTAL
Intervention: Pull-ups
Number of subjects: 61

Group type: COMPARATOR
Intervention: Diapers
Number of subjects: 61
Study: 11910567

Group type: EXPERIMENTAL
Intervention: TAC plus GEL
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: TAC plus HAS
Number of subjects: 69

Group type: COMPARATOR
Intervention: HAS
Number of subjects: 69

Group type: COMPARATOR
Intervention: GEL
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 69
Study: 10325997

Group type: EXPERIMENTAL
Intervention: 12 mg anthocyanosides
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 24 mg anthocyanosides
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 36 mg anthocyanosides
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7895921

Group type: EXPERIMENTAL
Intervention: Training with black horizontal and vertical line segments arranged as Ls, Ts, or +s on a pink background
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Delayed recognition by younger infants (3 months)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Training and testing conditions for 6-month-old infants
Number of subjects: 2
Study: 2707638

Group type: EXPERIMENTAL
Intervention: Elemental calcium 1200 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 330307

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (30 ml each 1/2 hr until eight doses, total dose of 4.2 g)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (higher dose of 8.2 g over 3 1/2‐hr treatment period)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate and placebo
Number of subjects: 169
Study: 7054318

Group type: EXPERIMENTAL
Intervention: CR virus vaccine
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 31126567

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Occlusal splint
Number of subjects: 20
Study: 30143479

Group type: EXPERIMENTAL
Intervention: Web-based smoking cessation intervention
Number of subjects: 2637

Group type: EXPERIMENTAL
Intervention: Web-based survey modality
Number of subjects: 2637

Group type: EXPERIMENTAL
Intervention: Recruitment through Facebook
Number of subjects: 2637

Group type: EXPERIMENTAL
Intervention: Recruitment through survey panel
Number of subjects: 2637

Group type: EXPERIMENTAL
Intervention: Recruitment through free internet sources
Number of subjects: 2637

Group type: EXPERIMENTAL
Intervention: Recruitment through traditional media
Number of subjects: 2637

Group type: EXPERIMENTAL
Intervention: Recruitment through Google ads
Number of subjects: 2637
Study: 27029708

Group type: EXPERIMENTAL
Intervention: AE37 + GM-CSF
Number of subjects: 298

Group type: COMPARATOR
Intervention: GM-CSF alone
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: AE37 + GM-CSF (IHC 1+/2+)
Number of subjects: 298

Group type: COMPARATOR
Intervention: GM-CSF alone (IHC 1+/2+)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: AE37 + GM-CSF (Triple-negative breast cancer)
Number of subjects: 298

Group type: COMPARATOR
Intervention: GM-CSF alone (Triple-negative breast cancer)
Number of subjects: 298
Study: 24423299

Group type: EXPERIMENTAL
Intervention: Heparin administration in nonpregnant women (n = 8, 15, 16)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Heparin administration in nonpregnant women
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Heparin administration
Number of subjects: 94
Study: 22753918

Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg once daily
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg once daily in KRAS wild-type tumors
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg once daily in KRAS wild-type/EGFR wild-type tumors
Number of subjects: 188

Group type: COMPARATOR
Intervention: Erlotinib 150 mg once daily
Number of subjects: 188

Group type: COMPARATOR
Intervention: Erlotinib 150 mg once daily in KRAS wild-type tumors
Number of subjects: 188

Group type: COMPARATOR
Intervention: Erlotinib 150 mg once daily in KRAS wild-type/EGFR wild-type tumors
Number of subjects: 188
Study: 20185783

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg tenecteplase
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg tenecteplase
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg tenecteplase
Number of subjects: 112

Group type: COMPARATOR
Intervention: 0.9 mg/kg rtPA
Number of subjects: 112
Study: 17681470

Group type: EXPERIMENTAL
Intervention: ICU liaison nurse intervention
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group with standard transfer protocol
Number of subjects: 115
Study: 14599251

Group type: EXPERIMENTAL
Intervention: Greater empathic accuracy when partner's thoughts and feelings were relationship-threatening.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower empathic accuracy when partner's thoughts and feelings were nonthreatening.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observer ratings of the degree to which partners tried to avoid the discussion issue.
Number of subjects: 0
Study: 11064762

Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms/kg) + DEC (6 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms/kg) + Albendazole (400 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: DEC (6 mg/kg) + Albendazole (400 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: DEC (6 mg/kg) + Ivermectin (200 micrograms/kg)
Number of subjects: 40
Study: 9232072

Group type: EXPERIMENTAL
Intervention: Cardioplegia with continuous warm blood
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cardioplegia with intermittent cold blood with warm reperfusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cardioplegia with intermittent cristalloid using SLF11 solution
Number of subjects: 60
Study: 8399865

Group type: EXPERIMENTAL
Intervention: Penicillin V (2 g)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amoxicillin (3 g)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2439783

Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg/d
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bisoprolol 20 mg/d
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg/d
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg/d
Number of subjects: 42
Study: 28244003

Group type: EXPERIMENTAL
Intervention: Self-regulatory intervention (three sessions with a health psychologist)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 64
Study: 25425539

Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg once a day for 3 months
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 23527823

Group type: EXPERIMENTAL
Intervention: Inhaled dry powder apomorphine (VR040)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22036610

Group type: COMPARATOR
Intervention: Single treatment pass with Q‐switched alexandrite laser (5.5 J/cm(2), 755 nm, 100‐nanosecond pulse duration, 3‐mm spot size)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4 treatment passes with Q‐switched alexandrite laser, 20 minutes apart (R20 method)
Number of subjects: 12
Study: 19469686

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (intracranial temperature of 34.5 +/- 0.2 degrees C, maintained for 72 h, n = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normothermia (intracranial temperature of 38.0 +/- 0.5, n = 10)
Number of subjects: 22
Study: 17430659

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy followed by adjuvant chemotherapy (weekly cisplatin 25 mg/m2 for 6 weeks, radiotherapy at 2 Gy/day to a total of 70 Gy, followed by cisplatin 25 mg/m2 and 5‐fluorouracil 1000 mg/m2 for 3 days every 3 weeks for 3 cycles)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy followed by adjuvant chemotherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 80
Study: 15675213

Group type: EXPERIMENTAL
Intervention: Disposable Portex LMA (PLMA)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard reusable LMA
Number of subjects: 138

Group type: COMPARATOR
Intervention: Reusable LMA
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Disposable PLMA
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 138
Study: 11902595

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (Copaxone)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 9591916

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study: 7888536

Group type: EXPERIMENTAL
Intervention: Didanosine (specific dosage and duration not mentioned)
Number of subjects: 0
Study: 3540668

Group type: EXPERIMENTAL
Intervention: Oral calcium (2000 mg daily)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Percutaneous 17 beta‐estradiol (combined with progesterone during the second year)
Number of subjects: 43
Study: 31195326

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 1000–3000 mg/day
Number of subjects: 343

Group type: COMPARATOR
Intervention: Topiramate (TPM) 200–400 mg/day
Number of subjects: 343
Study: 28447206

Group type: EXPERIMENTAL
Intervention: Urate-lowering therapy (ULT) for 6 months
Number of subjects: 46
Study: 25963221

Group type: EXPERIMENTAL
Intervention: TAVR in frail patients
Number of subjects: 244

Group type: COMPARATOR
Intervention: TAVR in nonfrail patients
Number of subjects: 244
Study: 24240384

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (LA) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21888656

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment during pregnancy
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control (no praziquantel treatment)
Number of subjects: 215
Study: 18539339

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17854525

Group type: EXPERIMENTAL
Intervention: High-dose GnRH antagonist (2 mg/day) + recombinant LH (375 IU/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (0.25 mg/day GnRH antagonist)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-dose GnRH antagonist + recombinant LH
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 15502029

Group type: EXPERIMENTAL
Intervention: Oral administration of IV fentanyl formulation (approximately 10‐15 microg/kg; maximum, 400 microg)
Number of subjects: 10
Study: 11903396

Group type: EXPERIMENTAL
Intervention: ANP 0.025 microg/kg/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BNP 0.025 microg/kg/min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9840314

Group type: EXPERIMENTAL
Intervention: Ketoacid-aminoacid-supplemented very low protein diet (diet K, 0.28 g/kg/d)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Amino acid-supplemented very low protein diet (diet J, 0.28 g/kg/d)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Low protein diet (diet L, 0.575 g/kg/d)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual protein diet (diet M, 1.2 g/kg/d)
Number of subjects: 66
Study: 8270442

Group type: EXPERIMENTAL
Intervention: Etanidazole (12 grams/meter2)
Number of subjects: 42
Study: 2492422

Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride (n = 24)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (n = 24)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lithium carbonate (n = 24)
Number of subjects: 72
Study: 30997631

Group type: COMPARATOR
Intervention: PEDEM supplementation at 12 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: PEDEM supplementation at 14 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PEDEM supplementation (various doses)
Number of subjects: 8
Study: 28064170

Group type: EXPERIMENTAL
Intervention: Peak oxygen consumption (VO2peak) measured in a maximal exercise test on cycle ergometer in men
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Peak oxygen consumption (VO2peak) measured in a maximal exercise test on cycle ergometer in women
Number of subjects: 68
Study: 26573069

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily for 2 years
Number of subjects: 908

Group type: COMPARATOR
Intervention: Observation (no further therapy)
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily for 2 years (high-risk subgroup)
Number of subjects: 908

Group type: COMPARATOR
Intervention: Observation (no further therapy) (high-risk subgroup)
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily for 2 years (centrally reviewed high-risk subgroup)
Number of subjects: 908

Group type: COMPARATOR
Intervention: Observation (no further therapy) (centrally reviewed high-risk subgroup)
Number of subjects: 908
Study: 23075258

Group type: EXPERIMENTAL
Intervention: Postcard intervention (monthly for five months plus usual care)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 201
Study: 21861998

Group type: EXPERIMENTAL
Intervention: Interpretation of a person's choice of toys based on her true or false beliefs about which toys were present.
Number of subjects: 0
Study: 19369371

Group type: EXPERIMENTAL
Intervention: LE-0.26
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LE-30
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LE-170
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 17039509

Group type: EXPERIMENTAL
Intervention: StarClose
Number of subjects: 596

Group type: COMPARATOR
Intervention: Manual Compression
Number of subjects: 596
Study: 15295410

Group type: EXPERIMENTAL
Intervention: 17-segment scores derived from 20-segment scores using algorithm 2
Number of subjects: 16020

Group type: COMPARATOR
Intervention: 20-segment perfusion scores
Number of subjects: 16020

Group type: COMPARATOR
Intervention: derived 17-segment scores
Number of subjects: 16020

Group type: EXPERIMENTAL
Intervention: 17-segment model
Number of subjects: 16020

Group type: EXPERIMENTAL
Intervention: Conversion algorithm 2
Number of subjects: 16020

Group type: EXPERIMENTAL
Intervention: Optimal prognostic cutoff value for either model
Number of subjects: 16020
Study: 11369630

Group type: EXPERIMENTAL
Intervention: Filgrastim 10 microg/kg per day subcutaneously from day 1 through neutrophil recovery
Number of subjects: 42
Study: 9635705

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Control (no preoperative radiotherapy)
Number of subjects: 1147
Study: 1927938

Group type: EXPERIMENTAL
Intervention: Sustained-release isosorbide dinitrate 120 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem 120 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combined therapy of isosorbide dinitrate and diltiazem
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6314720

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid (0.6%)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Polyglactin 910 (0.7%)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Polyglactin 910
Number of subjects: 306
Study: 30661513

Group type: EXPERIMENTAL
Intervention: Vibegron 50 mg (V50)
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Vibegron 100 mg (V100)
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Tolterodine extended release 4 mg (TER4)
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395
Study: 28329397

Group type: EXPERIMENTAL
Intervention: Resveratrol (2-3 g/daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29809375

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg per oral once daily for three months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg per oral once daily for three months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 23485476

Group type: EXPERIMENTAL
Intervention: rilonacept 80 mg
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: rilonacept 160 mg
Number of subjects: 248

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 248
Study: 21206331

Group type: EXPERIMENTAL
Intervention: Intravenous nafamostat mesilate
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 20441124

Group type: EXPERIMENTAL
Intervention: Vitro ceramic
Number of subjects: 15

Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 15
Study: 17031391

Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid (CLA) (Clarinol)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 118
Study: 15359356

Group type: EXPERIMENTAL
Intervention: Mineral water HB (bicarbonate-rich), 1 liter per day for 28 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mineral water HS (sulfate-rich), 1 liter per day for 28 days
Number of subjects: 60
Study: 11344383

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) 20 ng/kg/min
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) 10 ng/kg/min
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 9884269

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 144

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 144